Gataparsen

Drug Profile

Gataparsen

Alternative Names: ISIS 23722; LY-2181308; Survivin ASO

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Eli Lilly
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action BIRC5 protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 18 Apr 2012 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
  • 18 Apr 2012 Discontinued - Phase-II for Non-small cell lung cancer in Belgium (IV)
  • 18 Apr 2012 Discontinued - Phase-II for Non-small cell lung cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top